Earlier, we tested the efficacy of RD2RD2 in an AD specific mouse model overexpressing a double mutation of amyloid precursor protein and presenilin 1 (APP/PS1) by intraperitoneal treatment for four weeks with either RD2RD2 or placebo. Here, APP is linked to Alzheimer disease.